RECENT ADVANCES IN CHEMOTHERAPY

Antimicrobial Section 3

Proceedings of the 14th International Congress of Chemotherapy, Kyoto, 1985

Edited by Joji Ishigami

UNIVERSITY OF TOKYO PRESS
## §11. Miscellaneous Antimicrobial Agents

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacokinetics of Teicoplanin after Repeated i.m. Injections</td>
<td>G. Buniva and L. Cavenaghi</td>
<td>1897</td>
</tr>
<tr>
<td>The Pharmacokinetics and Tissue Penetration of Teicoplanin</td>
<td>J. M. Andrews et al.</td>
<td>1899</td>
</tr>
<tr>
<td>Treatment of Gram-positive Bacterial Infections with Teicoplanin:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Aspects</td>
<td>D. Felmingham et al.</td>
<td>1901</td>
</tr>
<tr>
<td>Clinical Study on the Effectiveness and Tolerability of Teicoplanin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caused by Staphylococci and Enterococci</td>
<td>R. F. Frongillo et al.</td>
<td>1903</td>
</tr>
<tr>
<td>Teicoplanin in the Treatment of Infection Caused by Gram-positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisms</td>
<td>A. H. Williams et al.</td>
<td>1905</td>
</tr>
<tr>
<td>Clinical Efficacy of Teicoplanin Alone in Severe Methicillin-resistant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gram-positive Septicemia</td>
<td>Y. Van Laethem et al.</td>
<td>1907</td>
</tr>
<tr>
<td>Profile of a New Phosphonic Acid Antibiotic, Fosmidomycin</td>
<td>H.-P. Kuemmerle and F. De Santis</td>
<td>1909</td>
</tr>
<tr>
<td>Pharmacokinetics in Children of a New Fosfomycin Derivative with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improved Bioavailability</td>
<td>D. Pavesio et al.</td>
<td>1911</td>
</tr>
<tr>
<td>Clinical Usefulness of Fosfomycin in Patients with Allergy to β-Lactam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotics</td>
<td>K. Suzuki and H. Tamai</td>
<td>1913</td>
</tr>
<tr>
<td>Experimental Studies of Some Derivatives of Rifamycin SV</td>
<td>V. Dimova et al.</td>
<td>1915</td>
</tr>
<tr>
<td>Main Human Urinary Metabolites of the Spiropiperidyl Rifamycin LM 427:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolation and Biological Properties</td>
<td>D. Ungheri et al.</td>
<td>1917</td>
</tr>
<tr>
<td>Activity of LM 427 on <em>Legionella</em> spp.: <em>In vitro</em> Study and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracellular Killing</td>
<td>D. Ungheri and A. Sanfilippo</td>
<td>1919</td>
</tr>
<tr>
<td><em>In vitro</em> Activity of Coumermycin A₁ and Other Newer and Older</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antistaphyloccocal Agents against <em>Staphylococcus aureus</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Avlami et al.</td>
<td></td>
<td>1921</td>
</tr>
<tr>
<td>Coumermycin: <em>In vitro</em> Comparison with Ampicillin, Benzylpenicillin,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clindamycin, Cloxacillin, Doxycycline, Erythromycin, Netilmicin and</td>
<td></td>
<td>1923</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>A. Digranes et al.</td>
<td></td>
</tr>
<tr>
<td>Comparative Efficacy and Toxicity of Trimethoprim-Sulfamethoxazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>versus Vancomycin in the Therapy of Serious <em>S. aureus</em> Infections</td>
<td>N. Markowitz et al.</td>
<td>1925</td>
</tr>
</tbody>
</table>
Pharmacological and Clinical Studies on Clofoctol, a New Antibacterial
Non-antibiotic Agent
M. Del Tacca et al. ........................................... 1927
Inhibition of Escherichia coli Dihydropteroate Synthase
by 6-Amino-5-nitrosoisocytosines
R. Ferone et al. ........................................... 1929
The Incidence of Trimethoprim Resistance amongst Bacteria Isolated
from Significant Bacteriuria in Vellore, South India
H.-K. Young et al. ........................................... 1930
Pharmacokinetics of Brodimoprim in Serum and Skin Blister Fluid
T. Kalager et al. ........................................... 1932
UK-49,858: A New Triazole Antifungal Drug with Novel Pharmacokinetic
Properties in Laboratory Animals
M. S. Marriott et al. ........................................... 1934
The Antifungal Activity of UK-49,858 in Animal Models of Superficial Infections
M. S. Marriott et al. ........................................... 1936
Early Clinical Experience with UK-49,858 in Human Volunteers and Patients
S. Jevons et al. ........................................... 1938
UK-49,858: In vitro Activity of a Potent Oral Agent against Systemic
Fungal Infections
K. Richardson et al. ........................................... 1940
Antifungal Activity of New Azoles
J. Van Cutsem and P. A. J. Janssen ........................................... 1942
Methiodine, a New Substituted Pyrimidine-antimycotic: Evaluation
of Antifungal Activity
H. Imamura et al. ........................................... 1944
SF 86-327: Results of Phase II Studies with a New Antifungal Agent for Oral
and Topical Application
A. Stephen et al. ........................................... 1946
An Open Clinical Therapeutic Study on the Effectiveness of SN 105-843 (Naftifin)
Cream in Patients with Dermatophyte Infection
H. C. Ting ........................................... 1948
Allylamines: A Novel Therapeutic Option in the Treatment of Fungal Skin Infections
O. Male et al. ........................................... 1950
Isolation of Candida albicans Mutants Sensitive to Antifungal Imidazoles
Y. Mikami et al. ........................................... 1952
Therapy of Paracoccidioidomycosis with Itraconazole in a Murine Model
J. G. McEwen et al. ........................................... 1954
Single Dose Pharmacokinetics of Rimantadine in Children
E. L. Anderson et al. ........................................... 1955
Antimonials Therapy (HPA-23) Therapy in Patients with AIDS or Prodromes
J. C. Chermann et al. ........................................... 1957
Selective Anti-herpesvirus Activity of BV-AraU
H. Machida et al. ........................................... 1959
Suppression of Visible Lesions of Genital Herpes Simplex Recurrences during
Chronic Dosing with Oral Acyclovir
S. Sacks et al. ........................................... 1961
Effect of Antiviral Drugs on the Dissemination of Herpes Simplex Virus
in Sensory Ganglia
R. J. Klein ........................................... 1963
Nature of Resistance to Acycloguanosine in a Clinical Isolate of Herpes Simplex
Virus Type 1
G. Palù \textit{et al.} .......................................................... 1965

Therapy of Recurrences of Genital Herpes with Topical Interferon
L. Eron \textit{et al.} .......................................................... 1967

The Inhibitory Effect of Halovinyl Deoxyuridine on Varicella-zoster Virus Replication and Deoxynucleotide Metabolism
T. Yokota \textit{et al.} .......................................................... 1969

IDU-resistant but Thymidine Kinase-positive Strain of Varicella-zoster Virus
S. Shigeta \textit{et al.} .......................................................... 1971

Chorioretinitis in an AIDS Patient Treated Successfully with DHPG
L. R. Mathiesen \textit{et al.} ............................................... 1973

Comparative Evaluation of Safety of Intranasal Interferon Alpha-2 and Placebo in a Population of Healthy Individuals Aged 64 to 85
D. C. Robbins \textit{et al.} .................................................. 1975

Use of a Persisting Type 1 Herpesvirus-induced Cutaneous Infection in Nude Mice for Evaluation of Antiviral Substances
J. H. Huffman \textit{et al.} .................................................. 1977

\section{12. Internal Medicine and Pediatrics}

Treatment of Infective Endocarditis: A Recent Ten-year Experience
T. Keys \textit{et al.} ............................................................. 1981

\textit{Staphylococcus aureus} Endocarditis: Evaluation of \textit{in vitro} and \textit{in vivo} Factors Affecting Treatment in 119 Cases
N. Frimodt-Møller and F. Espersen ..................................... 1983

\textit{Staphylococcus aureus} Bacteremias: New Patterns of Antimicrobial Resistance
M. D. Appleman \textit{et al.} .................................................. 1985

Prospective, Randomized Study of Cefotaxime vs Netilmicin vs Cefotaxime + Netilmicin in Treating Serious Sepsis
R. Sage \textit{et al.} ............................................................. 1986

Single Daily Administration of Ceftriaxone vs Chloramphenicol, Ampicillin or Cefotaxime Treatment in Childhood Meningitis
H. Peltola \textit{et al.} .......................................................... 1988

Ceftriaxone in the Treatment of Purulent Bacterial Meningitis
M. A. Barros and F. Ornildo ............................................. 1990

Activity of Ceftriaxone in the Treatment of Sepsis and Meningitis
G. Giardroni Grassi ......................................................... 1992

Short Term Treatment of Typhoid Fever with Ceftriaxone
H. Y. Chung \textit{et al.} ..................................................... 1994

Three-day Treatment of Typhoid Fever in Adults: Randomized, Comparative Study with Ceftriaxone vs Standard 14-day Course with Chloramphenicol
R. Lasserre \textit{et al.} ....................................................... 1996

Ceftriaxone in the Treatment of Typhoid Fever
M. A. Barros and B. Oliveira ............................................ 1998

Increasing Fastidious Pathogens of Infective Endocarditis
Y. Sawae \textit{et al.} .......................................................... 2000
The Role of Third-generation Cephalosporins in the Treatment of Bacterial Endocarditis
K. Bruch .................................................. 2002
Rifampicin with Co-trimoxazole in Endocarditis Due to Methicillin-resistant Staphylococcus: Report of Three Cases
A. E. Parrinello et al. .................................. 2004
Emergence of Enterococci as Important Pathogens in Patients with Malignant Diseases
K. Rolston et al. ......................................... 2006
Serratia Bacteremia: An Analysis of 50 Episodes
M. Garcia De La Torre et al. ........................... 2008
The Cerebrospinal Fluid Penetration of Fusidic Acid and the CSF Bactericidal Activity against Staphylococcal Species
I. W. Fong et al. ......................................... 2010
Patterns of Piperacillin Levels in Neurosurgical Patients with Slightly to Moderately and with Severely Impaired Blood-CSF-barrier
O. Brückner and M. Trautmann ....................... 2012
Cefotaxime in Childhood Meningitis
H. Lecour et al. .......................................... 2014
Cefotaxime Therapy in Gram-negative Bacillary Meningitis
S. El-Krinawi and M. Alkan ............................ 2016
Cefmenoxime Penetration into Cerebrospinal Fluid of Patients with Bacterial Meningitis
G. Humbert et al. ........................................ 2018
Ceftriaxone in Gram-negative Bacillary Meningitis
B. Sathapatayavongs et al. ............................... 2020
Antimicrobial Activity of Ofloxacin against Clinical Isolates of Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis
H. J. Dabernat et al. .................................... 2022
Salmonella Bacteremia in the Compromised Host:
A Retrospective Survey in 27 Patients
J. W. van 't Wout et al. ................................ 2024
Treatment of Gram-negative Pneumonia in ICU Patients Using a Combination of Selective Decontamination of the Oral Cavity and Antibiotics Administered Both Intravenously and by Aerosol
Ch. P. Stoutenbeek et al. ............................... 2026
The Efficacy of Cefmenoxime in Respiratory Infection
H. Tanimoto ............................................. 2028
Tissue Penetration of Cefamandole and Tobramycin in Patients with Suppurative Lung Disease
L. D. Liebowitz et al. .................................. 2030
Efficacy of Ceftizoxime Administered Twice Daily for the Treatment of Serious Infections in Hospitalized Patients
A. L. Lentnek et al. ..................................... 2032
Amikacin in Complicated UTI and Gram-negative Sepsis:
Clinico-pharmacokinetic Evaluation in Renal Failure
R. Konstantinović ....................................... 2034
Seven-year Surveillance of Nosocomial Infections in Obstetrics and Gynecology
H.A. Hirsch et al. ...................................... 2036
Clinical Studies on Pneumonia Due to *Mycoplasma pneumoniae*  
Y. Kobayashi *et al.* .................................................. 2038

Immunological Studies on Lower Respiratory Tract Infection with  
*Pseudomonas aeruginosa* in Diffuse Panbronchiolitis  
K. Yoshimura *et al.* .................................................. 2040

Evaluation of the Systemic and Local Host Defence Mechanism in Respiratory  
Infections  
A. Okano *et al.* ...................................................... 2042

Early Onset Pneumonia: A Multicenter Study in Intensive Care Units  
M. Langer *et al.* ...................................................... 2044

Comparative Clinical Evaluation of Moxalactam with Cefoxitin in Hospital-acquired  
Aspiration Pneumonia  
B. Khandheria *et al.* .................................................. 2046

Aztreonam or Ceftazidime as Single Agents versus Ticarcillin and Either Netilmicin  
or Tobramycin as Combined Therapy in the Management of Gram-negative  
Bacterial Pneumonia  
L. A. Cone *et al.* ...................................................... 2048

Enoxacin in Lower Respiratory Tract Infections  
W. J. A. Wijnands *et al.* ............................................. 2050

Burn Immunity and Bacterial Infection  
M. Ando and Y. Ando .................................................... 2053

Hospital-acquired Bacteremia and Fungemia in Adults:  
Analysis of Factors Influencing Prognosis  
X. Latorre *et al.* ...................................................... 2055

Analysis of the Importance of Aminoglycoside-resistant Enterobacteriaceae  
in a Teaching Hospital  
R. J. Cutler *et al.* .................................................... 2057

The Nosocomial Infection in the Surgical Department:  
The Study of 6,415 Surgical Patients during 1980 and 1982  
J.-P. Kim *et al.* ....................................................... 2059

Importance of Coagulase-negative Staphylococci in Patients with Cancer  
K. Rolston *et al.* ...................................................... 2061

Epidemic Spread of Multiresistant *Pseudomonas aeruginosa* in a Cystic Fibrosis Center  
S. S. Pedersen *et al.* ............................................... 2063

The Management of Nosocomial Infections in Chronic Uraemic Patients  
M. Papadimitriou *et al.* ............................................. 2065

Association of High Serum Bactericidal Titers and Serum Concentration  
of Vancomycin with Favorable Outcome in Methicillin-resistant  
*Staphylococcus* Infections  
J. J. Garaud *et al.* .................................................... 2067

Intravenously Administered Apalcillin in the Treatment of Aerobic and Anaerobic  
Infections in Hospitalized Patients  
M. Gurwith *et al.* ..................................................... 2069

Endotoxin Release from Bacteria Exposed to Ciprofloxacin and Other Bactericidal  
Antibiotics  
J. Cohen and J. S. McConnel ........................................... 2071

Protection from Endotoxaemia: A Rat Model of Plasmapheresis and Specific  
Adsorption with Polymyxin B  
J. Cohen *et al.* ........................................................ 2073
Studies on the Antiendotoxin Properties of Taurolin in Animals and Man
M.K. Browne et al. ................................................................. 2075

E. coli Endotoxins Influence Drinking Behavior in the Rat:
Role of Preoptic Prostaglandins
A. P. Caputi et al. ................................................................. 2077

Clinical Efficacy of Aspoxicillin on Severe Infections with Underlying Blood Diseases
H. Kawagoe et al. ................................................................. 2079

Nafcillin in Combination with Aztreonam or Tobramycin for Empiric
Therapy of Febrile Granulocytopenic Patients
S. J. Rehm and T. B. Dudzinski ............................................ 2081

A Preliminary Report of a Randomized Trial of Timentin and Tobramycin versus
Piperacillin and Tobramycin in Febrile Neutropenic Patients
M. J. Mackie et al. ................................................................. 2083

A Collaborative Trial of Cefoperazone Plus Tobramycin versus Cefoperazone Plus
Tobramycin with Tobramycin Discontinued after 4 Days versus Mezlocillin
Plus Tobramycin as Empiric Treatment in Febrile Neutropenic Patients
J. Phair et al. ................................................................. 2085

Piperacillin Plus Cefotaxime or Ticarcillin Plus Cefoxitin as Empiric Therapy
in Febrile Neutropenic Patients
J. L. Harkness et al. ................................................................. 2087

Effects of Cefmetazole on Infections Accompanying Granulocytopenia in Blood
Disorders
F. Takaku et al. ................................................................. 2089

Clinical Evaluation of Combination of Cefmetazole and Piperacillin in the Treatment
of Infections in Patients with Acute Leukemia
T. Nagao et al. ................................................................. 2091

Combination Therapy of Cefmenoxime and Aminoglycosides for Infections
in the Patients with Hematologic Diseases
K. Toyama et al. ................................................................. 2093

Clinical Study on Combined Therapy with Cefmetazole
S. Nakayama et al. ................................................................. 2095

Ceftazidime Therapy in the Immune-suppressed Host
M. E. Williams et al. ................................................................. 2097

Prophylactic Acyclovir and Therapeutic Ceftazidime for Infections during
Induction Treatment for Acute Leukemia in Adults
B. Lönnqvist et al. ................................................................. 2099

Antibiotic Combination Therapy with Piperacillin and Cefmenoxime in
Immuno compromised Patients
F. Vogel et al. ................................................................. 2101

Cefotaxime Plus Amikacin Followed by Flucloxacillin then Amphotericin
B for Febrile Neutropenic Patients
W. J. Spicer et al. ................................................................. 2103

Randomized Comparison of Netilmicin and Piperacillin with Tobramycin
and Piperacillin in the Empiric Therapy of Infections in Compromised Hosts
J. Bernstein et al. ................................................................. 2105

Choice of Empiric Antibiotics: An Epidemiologic Study of the Activity
of Broad-spectrum β-Lactams and Aminoglycosides against Bacteria from
Granulocytopenic or Severely Traumatized Patients
J. Tenney et al. ................................................................. 2107
An Empirical Trial of Antibiotics in Febrile Neutropenic Patients
C. C. Kibbler et al. .......................................................... 2109

Ciprofloxacin versus Trimethoprim/Sulfamethoxazole Plus Colistin for Prevention
of Infection in Granulocytopenic Patients
A. W. Dekker et al. .......................................................... 2111

Combined Use of Second-generation Quinolones and β-Lactams or Aminoglycosides
in the Treatment of Infections in Granulocytopenic Patients
M. Bakhtiar et al. .......................................................... 2113

The Use of Norfloxacin in the Prophylaxis of Neutropenic Patients
M. Corrado et al. .......................................................... 2115

Clinical Studies of Combined Therapy with Mezlocillin, Cephem Antibiotics,
and Aminoglycosides against Infections Associated with Hematopoietic
Disorders
K. Itoh et al. .......................................................... 2117

Comparative Study of Piperacillin Plus Amikacin with Piperacillin Plus Cefoperazone
in Granulocytopenic Patients with Fever: Initial Report of an Ongoing Study
M. Colon et al. .......................................................... 2119

Prophylactic Use of Ketoconazole in Immunocompromised Patients
S. Enenkel et al. .......................................................... 2121

Treatment of Life-threatening Cytomegalovirus Infections with i.v.
Foscarinet in Immunocompromised Patients
O. Ringdén et al. .......................................................... 2123

Cure of Cryptococcal Infections in Renal Transplant Patients with
Preservation of Renal Function
A. J. Watson et al. .......................................................... 2125

Cefotaxime in Severe Infections in Patients on Renal Replacement Therapy
K. Matousovic et al. .......................................................... 2127

Netilmicin/Piperacillin Therapy for Severe Systemic Infections: Preliminary Data.
A Comparative Multicenter Study vs Tobramycin/Piperacillin
R. R. Lorber et al. .......................................................... 2129

Clinical Experience with Netilmicin b.i.d. Therapy Plus Piperacillin in Severe
Systemic Infections
P. Leal del Rosal et al. .......................................................... 2131

Treatment of Human Botulism
H. Lecour .......................................................... 2133

Acquired Immunodeficiency Syndrome in Puerto Rico
H. F. Gorbea et al. .......................................................... 2135

Safety and Efficacy of Ceftazidime in Pediatric Infections
W. M. Gooch III .......................................................... 2137

Ceftazidime as Initial Empiric Therapy of Infections in Compromised Children:
Apropos of 96 Cases
C. Viscoli et al. .......................................................... 2139

The Efficacy of Ceftazidime in an Epidemic of Pseudomonas Infections in a
Neonatal Intensive Care Unit
R. Lippens et al. .......................................................... 2141

Neonatal Pharmacokinetic Characteristics of Ceftizoxime
W. M. Gooch III et al. .......................................................... 2143
Reduction of Morbidity and Mortality Rates of Neonatal Group B Streptococcal Disease through Early, Rapid Diagnosis and Prophylactic Chemotherapy
D. V. Lim et al. .................................................. 2145

Clinical Efficacy of Cefuroxime in the Treatment of Serious Pediatric Infections
C. M. Khurana .................................................. 2147

Clinical Evaluation of Efficacy and Tolerance of Fosfomycin in Severe Infections in Children
B. Grenier et al. .................................................. 2149

Z 1282 (Fosfomycin Trometamol): An Antibacterial Agent as a Single Dose Therapy of Lower Uncomplicated Urinary Tract Infection in Children
L. A. Varese et al. .................................................. 2151

Urinary Excretion of Antibiotics (Latamoxef, Ceftizoxime, Cefotaxime) in Infants with Refluxing or Obstructive Uropathy
T. Arai et al. .................................................. 2153

Randomized Double-blind Studies of Cefotaxime in Children Undergoing Appendicectomy
T. A. McAllister et al. .................................................. 2155

Cefotetan in the Treatment of Urinary Tract Infections in the Neonatal Period: Clinical and Pharmacokinetic Evaluation
G. Serra et al. .................................................. 2157

Timentin Therapy of Acute Bacterial Infections in Children
W. Gooch III et al. .................................................. 2160

Pharmacokinetics and Clinical Studies of Ceftizoxime Rectal Suppository in Pediatrics
S. Nakazawa et al. .................................................. 2162

Single-blind Comparison of Cefuroxime Axetil and Penicillin V as Therapy of Group A β-Hemolytic Streptococcal Pharyngitis
W. Gooch III et al. .................................................. 2164

Streptococci in the Throats of School Children in Saudi Arabia
A. A. Shokeir et al. .................................................. 2166

A. Nakamura et al. .................................................. 2169

Safety and Efficacy of Ceftizoxime Therapy of Acute Bacterial Meningitis of Childhood
W. M. Gooch III et al. .................................................. 2171

Developmental Pharmacokinetics of Piperacillin in Newborn Infants
T. T. Rubio et al. .................................................. 2173

Study of Cefotiam in the Treatment of Premature Infants and Neonates
Chemotherapy Study Group for Mother and Child (Director: R. Fujii) .................................................. 2175

Chemical Basis of Drug Binding Defects in Newborn Infants
S. J. Wadsworth and B. Suh .................................................. 2177

Ceftazidime Treatment for Neonatal Sepsis
D. Low et al. .................................................. 2179

Open Comparative Safety Pharmacokinetics and Efficacy Study of Mezlocillin Alone Compared with Ampicillin and Amikacin in the Treatment of Newborn Infants with Suspected or Confirmed Sepsis: First Course of Treatment
F. Wirth et al. .................................................. 2181

Advantages of i.v. Cefoperazone in Bowel Surgery in Children
E. Bingen et al. .................................................. 2182
§13. Urology

Multi-centre Study to Assess the Efficacy of Temocillin Used Prophylactically to Prevent Infection in Patients Undergoing Transurethral Resection of the Prostate
E. W. Taylor et al. ......................................................... 2187

Intravenous Apalcillin in the Treatment of Complicated Urinary Tract Infection
M. Lee et al. ................................................................. 2189

A Comparison of Enoxacin and Trimethoprim/Sulfametoxazole in the Treatment of Patients with Complicated Urinary Tract Infections
C. E. Cox ................................................................. 2191

A Comparison of Enoxacin and Trimethoprim/Sulfametoxazole in the Treatment of Patients with Complicated Urinary Tract Infections
S. J. Childs ............................................................... 2193

New Cephalosporins in the Treatment of Urinary Tract Infections and Respiratory Tract Infections in Hospitalized Patients: Clinical Review
G. Romanelli et al. ..................................................... 2195

One or Three Weeks Treatment of Acute Pyelonephritis? Result of a Double-blind Study with Pivampicillin Plus Pivmecillinam
J. Zbornik et al. ......................................................... 2197

Clinical Studies of Efficacy of Piperacillin against Complicated Urinary Tract Infections
T. Ikeuchi et al. ......................................................... 2199

Single-dose Therapy of Urinary Tract Infection with 1 g Cefotaxime
V. Prat et al. .............................................................. 2201

Ceftixaxone Therapy in Complicated Urinary Tract Infections: A Comparative Evaluation
L. Bernstein Hahn et al. ................................................ 2203

Treatment of Bacterial Cystitis with a Single Dose of Trimethoprim, Co-trimoxazole or Amoxycillin Compared with a Course of Trimethoprim
R. R. Bailey et al. ....................................................... 2205

A Comparative Trial of Three Different Single Dose Antibiotic Regimens for Uncomplicated Lower Urinary Tract Infection
R. Kemp et al. ............................................................. 2207

Norfloxacin versus Pipemidic Acid: A Comparative Microbiological and Clinical Study in Complicated Urinary Tract Infections
R. F. Frongillo et al. .................................................... 2209

Treatment of Non-complicated Lower Urinary Tract Infections with Fosfomycin Trometamol, an Orally Absorbed Salt of Fosfomycin, in a Short Course Therapy
M. Neuman et al. ....................................................... 2211

A New Fosfomycin Salt, Fosfomycin Trometamol (Z.1281): Pilot Trial of Its Effectiveness by Oral Single-dose in Primary, Uncomplicated Infections of the Urinary Tract
M. Moroni et al. ........................................................ 2214

Effect of Trimethoprim-Sulfamethopyrazine Association in Chronic Prostatitis of Different Etiologies
D. Di Trapani et al. ..................................................... 2216

Clinical Study of Chemotherapeutic Response on Three Types of Prostatitis Classified by Isolated Organisms
H. Tamai et al. .......................................................... 2218
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect of Residual Urine upon Chemotherapy in Complicated Cystitis:</td>
<td>2220</td>
</tr>
<tr>
<td>In vitro Experiments with a Bladder Model</td>
<td></td>
</tr>
<tr>
<td>Y. Ban et al.</td>
<td></td>
</tr>
<tr>
<td>Bacterial Count in Urine</td>
<td>2222</td>
</tr>
<tr>
<td>M. Kanematsu et al.</td>
<td></td>
</tr>
<tr>
<td>The Bacteria Contaminating in Total Spontaneous Voided Urine</td>
<td>2224</td>
</tr>
<tr>
<td>S. Ueda and K. Eto</td>
<td></td>
</tr>
<tr>
<td>Three-day and Seven-day Treatment of Acute Uncomplicated Cystitis</td>
<td>2226</td>
</tr>
<tr>
<td>S. Arakawa et al.</td>
<td></td>
</tr>
<tr>
<td>Recurrence Rate in Acute Uncomplicated Cystitis by Chemotherapy for Seven Days</td>
<td>2228</td>
</tr>
<tr>
<td>T. Hirose and Y. Kumamoto</td>
<td></td>
</tr>
<tr>
<td>Evaluation of Recurrence after Treatment of Acute Uncomplicated Cystitis</td>
<td>2231</td>
</tr>
<tr>
<td>K. Okada et al.</td>
<td></td>
</tr>
<tr>
<td>Background of the Patients with Complicated UTI Evaluated by the Criteria Proposed by the UTI Committee, Japan</td>
<td>2233</td>
</tr>
<tr>
<td>Y. Ban et al.</td>
<td></td>
</tr>
<tr>
<td>Type of Infection, Drug Sensitivity and Clinical Efficacy in Complicated Urinary Tract Infections</td>
<td>2235</td>
</tr>
<tr>
<td>Y. Shimizu et al.</td>
<td></td>
</tr>
<tr>
<td>Study of the “Poor” Cases Evaluated by the Criteria of UTI Committee on Treatment with New Cephems of the Third Generation</td>
<td>2237</td>
</tr>
<tr>
<td>H. Kishi et al.</td>
<td></td>
</tr>
<tr>
<td>Studies on Distribution of Bacterium and Antibiotic in Urine and Renal Tissue of Experimental Acute Pyelonephritic Dogs</td>
<td>2239</td>
</tr>
<tr>
<td>S. Tsuchida et al.</td>
<td></td>
</tr>
<tr>
<td>Duration of Treatment Proper for the Evaluation of Drug Efficacies in Complicated Urinary Tract Infection</td>
<td>2241</td>
</tr>
<tr>
<td>Y. Kawada et al.</td>
<td></td>
</tr>
<tr>
<td>Duration (Days) Required for Evaluation of Orally Administered Antimicrobial Agents against Chronic Complicated Urinary Tract Infections</td>
<td>2243</td>
</tr>
<tr>
<td>T. Matsumoto et al.</td>
<td></td>
</tr>
<tr>
<td>Comparison of Therapeutic Results in 5-day and 10-day Chemotherapy in Complicated Urinary Tract Infections</td>
<td>2245</td>
</tr>
<tr>
<td>S. Sakai et al.</td>
<td></td>
</tr>
<tr>
<td>Treatment of Urinary Tract Infections with Pefloxacin:</td>
<td></td>
</tr>
<tr>
<td>Efficacy, Safety and Pharmacokinetics</td>
<td>2247</td>
</tr>
<tr>
<td>R. Wittenberger and A. Bauernfeind</td>
<td></td>
</tr>
<tr>
<td>Clinical Studies of Antimicrobial Prophylaxis of Recurrent Urinary Tract Infection in Women: Long-term, Low-dose Cinoxacin Therapy</td>
<td>2249</td>
</tr>
<tr>
<td>H. Nakano et al.</td>
<td></td>
</tr>
<tr>
<td>Clinical and Bacteriological Evaluation of Ciprofloxacin in Treatment of UTIs of Para- and Tetraplegic Patients</td>
<td>2251</td>
</tr>
<tr>
<td>D. Sauerwein et al.</td>
<td></td>
</tr>
<tr>
<td>Clinical Experience in Complicated Urinary Tract Infection with Norfloxacin</td>
<td>2253</td>
</tr>
<tr>
<td>A. Jaupitre et al.</td>
<td></td>
</tr>
<tr>
<td>Clinical Evaluation of Lenampicillin (KBT-1585) in the Treatment of Acute Uncomplicated Cystitis: A Double-blind Comparative Study with Bacampicillin</td>
<td>2258</td>
</tr>
<tr>
<td>J. Kumazawa et al.</td>
<td></td>
</tr>
<tr>
<td>Single Dose Cefotaxime in Urinary Tract Infection</td>
<td>2260</td>
</tr>
<tr>
<td>B. F. Murphy et al.</td>
<td></td>
</tr>
</tbody>
</table>
A Comparative Study on Efficacy of Cefminox (MT-141) and Cefotaxime in the Treatment of Complicated Urinary Tract Infections  
J. Kumazawa et al. ........................................... 2262

MK-0787/MK-0791 Treatment of Patients with Urinary Tract Infection  
T. Tominaga et al. ........................................... 2264

An Open Parallel Study of Cefuroxime Axetil vs Cefaclor in the Treatment of Complicated Urinary Tract Infections  
P. Nikolaidis et al. ........................................... 2266

Once Daily Cefonicid versus Standard Dose Cefamandole in the Treatment of Urinary Tract Infections Due to Enterobacter Species  
C. E. Cox et al. ........................................... 2268

Preliminary Analysis: Efficacy of Ceftizoxime in the Therapy of Complicated Urinary Tract Infections Due to Gram-negative Organisms Resistant to Multiple Antibiotics Including Ceftizoxime  
C. E. Cox et al. ........................................... 2270

Perioperative Use of Antimicrobial Agents for Infectious Complications in Prostatic Surgery  
M. Shimamura et al. ........................................... 2272

Relapse of Infections after Treatment of Complicated Urinary Tract Infection and the Influence of Antibiotics in Urine to the Bacterial Test by Dip-slide  
J. Ishigami et al. ........................................... 2274

Studies on Drug Resistance in Escherichia coli Isolated from Urinary Tract Infection Patients  
P. K. Chang et al. ........................................... 2276

Detection of β-Lactamase in Urine and Its Significance in Chemotherapy for Urinary Tract Infection  
M. Yamaha et al. ........................................... 2278

Bacteriological and Architectural Studies of Infected Urinary Stones  
H. Takeuchi et al. ........................................... 2280

A Study of Urinary Tract Infections after Prostatectomy  
T. Doi et al. ........................................... 2282

Criteria for Diagnosis of Bacteriuria in Acutely Spinal Cord Injured Patients on Intermittent Catheterization  
M. J. Gribble et al. ........................................... 2284

Debridat Use in Micturition Disorders: Preliminary Report  
S. Giacobini et al. ........................................... 2286

Serious Bacterial Infections in Male Homosexuals  
L. A. Cone et al. ........................................... 2288

Preliminary Report on the Comparative Efficacy of Single Oral Doses of Amoxicillin/Probenecid vs. Cefuroxime Axetil/Probenecid in Uncomplicated Gonococcal Infections  
I. W. Fong et al. ........................................... 2290

Cefuroxime Axetil versus Augmentin for Oral Treatment of Non-complicated Urogenital Gonorrhoea in Males and Females  
M. F. Michel et al. ........................................... 2292

The Role of Chlamydia trachomatis and Ureaplasma urealyticum in Genital Tract Diseases  
Y. Ito et al. ........................................... 2294

Results of Treatment of Urinary Tract Infections with Cefotaxim  
J. Wencel et al. ........................................... 2296
A Comparison of Temocillin and Temocillin Plus Probencid in the Treatment of Gonococcal Urethritis
R. C. Ballard et al. .................................................. 2297

In vitro Susceptibility and Clinical Efficacy of Some New Antibiotics against Gonococci in Japan
S. Onodera et al. .......................................................... 2299

Antibiotic Sensitivity in Neisseria gonorrhoeae Related to Serovars and Auxotypes
I. Kallings et al. ............................................................... 2301

Activity of New Quinolone Antibiotics against Neisseria gonorrhoeae
H. Faruki et al. ............................................................... 2303

Ofloxacin, a New Quinolone or a New Pyridone Carboxylic Acid, in the Treatment of Gonococcal Urethritis
D. Tanphaichitra et al. .................................................. 2305

Effectiveness of Ofloxacin in the Treatment of Gonococcal and Nongonococcal Urethritis
J. Chen and T. C. Hsu .................................................... 2307

Antibiotic Therapy for Chlamydia, Ureaplasma and Mycoplasma Infections Associated with Genitourinary Infections and Unexplained Infertility
D. Portnoy ................................................................. 2309

Treatment of Acute Epididymitis with Minocycline
R. C. Ballard et al. .................................................. 2311

The Kinetics of Action of Inosine Pranobex
F. Hoehler et al. ......................................................... 2313

Kaposi’s Sarcoma and Non-Hodgkin’s Lymphoma in a Homosexual Male with Human T-cell Lymphotropic Retrovirus (HTLV III) Infection
H. P. Katner et al. ....................................................... 2315

Inosine Pranobex in the Management of Recurrent Genital Herpes Simplex Infections
A. Glasky and R. Miller ................................................ 2317

Ofloxacin in Treatment of Uncomplicated Gonococcal Urethritis
A. S. C. Chan et al. .................................................. 2319

Clinical Experience with Norfloxacin in the Treatment of Gonorrhea
M. Corrado et al. ...................................................... 2321

§14. Surgery, Gynecology and Obstetrics

Bacterial Analysis of Postoperative Infection Over Ten Years
Y. Yamada et al. .......................................................... 2325

Statistical Analysis of Postoperative Infection:
Changes in the Last 20 Years
A. Murakami et al. ...................................................... 2327

Fine Needle Aspiration Biopsy Culture in the Assessment of Soft-tissue Infections Treated with Antibiotics (in Humans)
J. Turnidge et al. ......................................................... 2329

A Randomized Double-blind Trial of Ceftizoxime vs Cefoxitin for Therapy of Lower Extremity Infections in Patients with Diabetes Mellitus and/or Peripheral Vascular Disease
C. Hughes et al. .......................................................... 2331

A Prospective Trial of Fucidic Acid and Gentamicin in Bone Cement
R. R. H. Coombs et al. ................................................ 2333
A Comparison of Cefsulodin and Conventional Therapy in Patients with Osteomyelitis Due to \textit{P. aeruginosa}
G. Trenholme \textit{et al.} .................................................. 2335

Latamoxef Disodium for Chronic Osteomyelitis
M. Beverly \textit{et al.} .................................................. 2337

A Randomized Comparative Study of Cefotetan and Cefotaxime in Patients with Various Traumatic Infections
H. Hessler ................................................................. 2339

Chemoprophylactic Implications of Enterococcal Infection in Surgery
J. I. Blenkharn ......................................................... 2342

Comparative Trial of Ceftizoxime, Cefotaxime and Moxalactam in Treatment of Bacterial Peritonitis
R. Nichols \textit{et al.} .................................................. 2344

Multicenter Comparative Study of the Safety and Efficacy of Ceftizoxime in Peritonitis
A. Lentnek \textit{et al.} .................................................. 2346

A Prospective Randomized Study of Cefotetan and Piperacillin against Netilmicin and Metronidazole in the Treatment of Patients Presenting with Generalized Peritonitis
G. Lindsay \textit{et al.} .................................................. 2348

Pharmacokinetics and Clinical Efficacy of Cefotaxime in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis
H. Hasegawa \textit{et al.} .................................................. 2350

Treatment of Bone Infections with Gentamicin-containing Plastic Beads: Prognostic Value of Different Bacteriological Parameters
E. Borderon \textit{et al.} .................................................. 2352

Efficacy and Safety of Ciprofloxacin in the Treatment of Patients with Skin and Soft Tissue Infections
L. Constable ............................................................. 2354

Oral Flora Reduction with Rifampicin
P. C. Appelbaum \textit{et al.} ............................................. 2356

Penetration of Five Cephalosporins, Cefamandole, Cephapirin, Cefotaxime, Cefoxitin, and Cefuroxime in Bone
E. J. Perea \textit{et al.} .................................................. 2358

Single Dose Perioperative Prophylaxis during Prostatectomy: A Comparative Study of Gentamicin and Cefotetan
R. D. Leach ............................................................... 2360

Chlorhexidine Irrigation Reduces Urinary Infections after Transurethral Operations: A Controlled Trial
R. A. Simpson \textit{et al.} .................................................. 2362

Hysterectomy Prophylaxis: Placebo vs Facultative vs Anaerobic Plus Facultative Antibiotics
P. J. McDonald \textit{et al.} .................................................. 2364

Latamoxef in Hysterectomy Prophylaxis: Influence on Septic Complications and Colonizing Flora
H. McDonald \textit{et al.} .................................................. 2366

Comparative Penetration of Various \textit{\beta}-Lactams into Purulent Ascites, Appendix Wall and Other Tissues from Patients with Acute Peritonitis Following Intravenous Administration
T. Nakamura \textit{et al.} .................................................. 2368
Perioperative Antibiotic Prophylaxis with Cefadroxil, Amikacin, and Metronidazole in Colorectal Surgery
T. Popiela et al. .................................................................................................................. 2370

Cefotetan versus Established Antibiotic Therapy in the Treatment of Acute Intra-abdominal Infections
I. G. Haynes et al. .................................................................................................................. 2372

Cefotetan, a New Cephamycin for the Treatment of Intra-abdominal Infections
G. Rodolico et al. .................................................................................................................. 2374

Antibiotic Management of Surgically Treated Gangrenous or Perforated Appendicitis: A Preliminary Comparison of Aztreonam and Clindamycin versus Gentamicin and Clindamycin
T. V. Berne et al. .................................................................................................................. 2376

Comparative Evaluation of Ceftizoxime and Cefoxitin in the Treatment of Intraabdominal Infections
M. A. Lou et al. .................................................................................................................... 2378

Clinical Evaluation of Cefmetazole Sodium in Complicated Gastroenterological Infections
T. C. Wei et al. ...................................................................................................................... 2380

Comparative in vitro Activity of Augmentin, Timentin, Cefotaxime, and Moxalactam against Bacteria Involved in Severe Postoperative Peritonitis
J. Carlet et al. ....................................................................................................................... 2382

Cefotaxime versus Ampicillin for Acute Cholecystitis Treated by Early Surgery: A Double-blind, Multicenter Trial
J. Lahtinen et al. ................................................................................................................... 2385

The Concentration of Cefmetazole in Hepatic Tissue in Children with Obstructive Jaundice Disease
T. Miyano et al. ................................................................................................................... 2387

Antibiotic Prophylaxis in Biliary Surgery
F. Castro Sousa et al. ............................................................................................................ 2389

Intracisional Antibiotic in Addition to Systemic Antibiotic Treatment Fails to Reduce Wound Infection Rates in Dirty Abdominal Surgery
F. Møesgaard et al. ............................................................................................................. 2391

Antibiotics in Acute Abdominal Surgery: The Combination of Ampicillin, Mecillinam and Metronidazole versus Cefoxitin Alone
B. Kasholm-Tengve and P. Bartholdson ............................................................................ 2393

Are Postoperative Wound Infections Prevented by an Intraoperative Use of Antibiotics (Cefmetazole) or Peritoneal Lavage?
T. Utsunomiya et al. ........................................................................................................... 2395

Evaluation of Efficacy of Prophylactically Used Antibiotics during Operation Administered Intravenously by Drip Infusion in Gastroenterological Surgery
M. Kunimatsu et al. ............................................................................................................ 2397

A Comparative Evaluation of Single Dose Cefotaxime and Cefuroxime in Prevention of Postoperative Infection Following Gastric Surgery
D. Gatehouse .................................................................................................................... 2399

A Comparative Evaluation of Cefotaxime and Cefamandole in the Prevention of Postoperative Wound Infection Following Abdominal Surgery
S. Sagar and N. Smith ......................................................................................................... 2401
Prophylactic Use of Cefotaxime in High-risk Biliary and Gastroduodenal Surgery: A Controlled Trial on Duration of Prophylaxis
F. Moesgaard et al. ................................................................. 2403

A Selective Policy of Antibiotic Administration in Biliary Surgery Does Not Reduce Morbidity
N. S. Ambrose et al. ................................................................. 2405

A Prospective Double-blind Controlled Trial of Antibiotic Prophylaxis in Biliary Surgery
E. P. Dewar et al. ................................................................. 2407

Prophylactic Use of Cefotaxime in Elective Biliary Surgery
D. Sykes and A. Wu ............................................................... 2409

A Multi-centre Study to Compare Piperacillin with Netilmicin and Metronidazole for Prophylaxis against Infection Following Elective Colorectal Operations
E. W. Taylor et al. ................................................................. 2411

Efficacy of Oral Antibacterial Prophylaxis with Kanamycin and Ofloxacin in Gastrointestinal Operation
T. Saito et al. ................................................................. 2413

A Study of Prophylactic Oral Antimicrobial Agents in Elective Colorectal Surgery
S. Ono and S. Kato ............................................................... 2415

Piperacillin versus Metronidazole for Prophylaxis of Postappendicectomy Infections: A Placebo-controlled, Double-blind Trial
J. Lahtinen et al. ................................................................. 2417

A Randomized Clinical Trial to Compare the Efficacy of a Single Preoperative Dose of Metronidazole, Cefotaxime or Moxalactam in Appendicectomy Prophylaxis: A Study of Early and Late Wound Infection
P. C. Gartell et al. ................................................................. 2419

A Comparison of Cefotaxime Alone and Cefotaxime Plus Metronidazole in the Management of Postoperative Wound Sepsis Following Emergency Appendicectomy
J. B. Bourke et al. ................................................................. 2421

A Comparative Study of Metronidazole Alone against Metronidazole and Cefotetan to Prevent Infection after Appendicectomy
E. W. Taylor et al. ................................................................. 2423

Ceftriaxone, a Long Acting Cephalosporin, with Metronidazole Is a More Effective Combination than Gentamicin with Metronidazole as a Single Dose Prophylaxis in Colorectal Surgery
A. Shepherd et al. ............................................................... 2425

Gentamicin Plus Metronidazole in Elective Colorectal Surgery: A Controlled Trial on Duration of Antibiotic Prophylaxis
M. Lykkegaard-Nielsen et al. ................................................................. 2427

Concentrations of Cefoperazone in Colonic Lumen: A Trial for Antibiotic Prophylaxis in Colorectal Surgery
J. P. Favre et al. ................................................................. 2429

Serum Pharmacokinetics of Prophylactic Antibiotics during Colorectal Surgery
D. W. Burdon et al. ................................................................. 2431

A Prospective Randomized Trial to Study the Bacteriological Efficacy of Tetracycline Lavage in Elective and Emergency Colorectal Operations
N. S. Ambrose et al. ................................................................. 2433
Comparison of Local Prophylaxis with Cloxacillin and Systemic Prophylaxis with Flucloxacillin in Pacemaker Surgery: A Randomized Double-blind Prospective Trial at Generator Replacements
G. Bluhm et al. ................................. 2435

Antibiotic Prophylaxis in Cardiovascular Surgery
S. Geroulanos et al. .......................... 2437

Antibiotic Prophylaxis in Vascular Reconstructive Surgery:
A Double-blind Placebo-controlled Study
A. M. Worning et al. ......................... 2439

Prophylactic Antibiotics in Pulmonary Surgery: How Long; Which Cases?
K. Moghissi et al. ............................ 2441

Antibiotic Prophylaxis with Oxacillin in Lower Limb Vascular Surgery
Ph. Canton et al. ............................. 2443

Cefamandole Prophylaxis for Clean Orthopaedic Surgery Requiring Prosthetic Devices
J. M. Gatell et al. ............................. 2445

Flucloxacillin and Ceftriaxone in the Perioperative Prophylaxis of Patients Undergoing Prosthetic Hip and Knee Surgery by a Prospective Randomized Trial
J. Ungemach and M. Winter .................. 2447

Cefonicid vs Cefamandole as Prophylaxis against Infections in Polytrauma Patients
E. Caplan et al. ............................... 2449

The Effects of the Peroral Combination of Pivampicillin/Pivmecillinam Given as a Perioperative Short Antibiotic Course in Conjunction with Transurethral Prostatic Resection
M. Grabe et al. ............................... 2451

The Effect of a Short and a Prolonged Perioperative Course of Ciprofloxacin Given in Conjunction with Transurethral Prostatic Resection
M. Grabe et al. ............................... 2453

A Prospective, Randomized Comparative Study of Cefazolin, Cefoxitin and Cefotaxime Used for Elective Surgical Prophylaxis: A Report of 1,037 Cases
W. V. Wojeski and R. N. Jones .......... 2455

Single Dose Antibiotic Prophylaxis in Major Abdominal Surgery
M. Edelmann and W. Cullmann ............ 2457

Study on Postoperative Wound Infections in the Surgery of the Digestive Tract: Relation between the Contaminants in the Surgical Field and the Isolated Pathogens from the Infected Wound, and Effect of Prophylactic Use of Cefmetazole
E. Konaga et al. ............................. 2459

A Comparison of Piperacillin with Cefotaxime as Prophylaxis in Elective Biliary Surgery with Analysis of High Risk Factors
I. R. Townend et al. ......................... 2461

Efficacy of Cefmetazole against Postoperative Infections in Surgery
H. Kanno et al. ............................... 2463

Prophylactic Effect of Pretreatment with Polymyxin B and Tinidazole on Postoperative Infection in Colorectal Surgery
T. Hirayama et al. ............................ 2465

A Multicentric Comparative Study of Cefotetan + Metronidazole vs Metronidazole Alone in the Prophylaxis of Wound Infection in Patients Undergoing Large Bowel Operations by a Prospective Randomized Trial
R. Hall et al. ............................... 2467
A Single Centre Study of Cefotetan Plus Metronidazole versus Three Dose Metronidazole Treatment in the Prophylaxis of Wound Infection in Patients Undergoing Large Bowel Surgery

P. W. R. Lee et al. ........................................................................................................... 2468

Emergence of Resistance against Prophylactically Used Antibiotics Is Prevented by Selective Decontamination of the Digestive Tract

Ch. P. Stoutenbeek et al. .................................................................................................. 2470

Perioperative Systemic Prophylaxis Using Cefotaxime during the Insertion of Ventriculo-peritoneal Shunts: A Prospective Study

A. Thierry et al. ................................................................................................................. 3472

An Open Controlled Comparison of Imipenem (MK-787/MK-791) vs Metronidazole Plus Cefuroxime in the Prevention of Infectious Morbidity

Ch. P. Stoutenbeek et al. .................................................................................................. 2470

Complicating Colorectal Surgery

G. L. J. Sutton et al. ........................................................................................................... 2474

Prophylaxis of Urinary Tract Infection and Sepsis Following Transurethral Resection of the Prostate

E. D. Crawford et al. ........................................................................................................... 2476

Antimicrobial Prophylaxis in Acute Abdominal Surgery: Comparison between Metronidazole-Gentamicin and Metronidazole-Fosfomycin

J. Lindhagen et al. .............................................................................................................. 2477

Patterns of Aerobic Flora in Vaginal Smears from Girls and Adult Women

I. Wachter et al. .................................................................................................................. 2479

Hormonal Background and *Ureaplasma urealyticum* Infection in Females

T. Iwasaka et al. ................................................................................................................ 2482

Amikacin Sulphate in Gynecological Infections

S. Mantalenakis et al. ......................................................................................................... 2484

A Comparative Study of Parenteral Cefotaxime and Mezlocillin in the Prophylactic Treatment of Hospitalized Patients Undergoing Vaginal Surgery (e.g. Vaginal Hysterectomy, Anterior or Posterior Colporrhaphy)

E. Goormans and F. Hogerhuis ........................................................................................ 2486

Prophylactic Antibiotics for Vaginal Hysterectomy: A Comparison of Cefotaxime and Penicillin G versus a Control Group

F. Fischbach et al. .............................................................................................................. 2488

Single-dose Mezlocillin Prophylaxis in Emergency Cesarean Section

R. Jaffe et al. ...................................................................................................................... 2490

Prophylactic Antibiotics in Obstetric and Gynecologic Surgery

M. Ishikawa et al. .............................................................................................................. 2492

Comparative Study of the Safety and Efficacy of Cefonicid versus Cefoxitin in Prevention of Postoperative Infectious Complications Following Gynecologic Surgery

S. F. Gordon .................................................................................................................... 2494

Studies on Bacterial Flora in Female Internal Genital Organs and Prevention of Postoperative Infection

M. Saitoh et al. .................................................................................................................. 2496

An Evaluation of Pelvic Tissue Levels Following Oral Administration of Enoxacin, a New Quinolone Antibiotic

S. A. Bates and M. G. Elder .............................................................................................. 2498

Evaluation of a New Method for the Study of Epithelium-associated Microbial Flora of the Vagina

E. T. Houang and Z. Ahmet ............................................................................................. 2500
Cefoperazone and Sulbactam versus Clindamycin and Gentamicin for Pelvic Infections
D. Hemsell et al. ................................................................. 2502

Study of Cefotiam Treatment during Perinatal Period in Patients in Obstetrics and Gynecological Fields
Chemotherapy Study Group for Mother and Child (Director: R. Fujii) .............. 2504
Mother-to-infant Transmission of Chlamydia trachomatis in Perinatal Period
J. Yasuda et al. .................................................................. 2506

Comparison of Cefonicid and Cefoxitin for Prophylaxis in Vaginal Hysterectomy
T. W. Littlejohn et al. ............................................................ 2508

Treatment of Post-cesarean Section Endoparametritis with Oral Cephadrine after Initial Response to Oral Cephadrine
S. G. McNeeley et al. ......................................................... 2510

Metronidazole for Treatment of Post-cesarean Section Endomyometritis
I. Amon and K. Amon .......................................................... 2512

The Efficacy of Antibiotic Prophylaxis in the Prevention of Endometritis
Following Cesarean Section Delivery
L. G. Donwitz and S. M. Norris .............................................. 2514

Antibiotic Prophylaxis in Cesarean Section: Cephalothin versus Mezlocillin
M. Alkan and J. R. Lieberman ............................................. 2516

A Comparison of Alternative Methods of Administering Prophylactic Antibiotics at Cesarean Delivery
S. G. McNeeley et al. ............................................................ 2519

A Randomized Study to Compare the Efficacy and Safety of Mezlocillin versus Clindamycin Plus Gentamicin in the Treatment of Postpartum Endometritis
S. Faro et al. ................................................................. 2521

A Randomized Study to Compare the Efficacy and Safety of Mezlocillin versus Cefoxitin in the Treatment of Postpartum Endometritis
S. Faro et al. ................................................................. 2523

A Randomized Study to Compare the Efficacy and Safety of Clindamycin Plus Gentamicin versus Cefoxitin in the Treatment of Postpartum Endometritis
S. Faro et al. ................................................................. 2525

Effects of Piperacillin, Clindamycin, Cefoxitin, Cefoperazone, Cefotaxime Tobramycin and Gentamicin in vitro on Polymorphonuclear Leucocytes from Leucopenic Patients and from Patients with Severe Pelvic Inflammatory Disease
L. C. Ford and H. A. Hammill ............................................ 2527

§15. Miscellaneous Infections

Successful Treatment of Candida Endophthalmitis by Intravenous Amphotericin B and Fluocytosine
O. Oelz et al. ................................................................. 2531

Management of Recurrent Vulvovaginal Candidiasis with Ketoconazole Prophylaxis
J. Sobel ........................................................................ 2533

Fungal Aeroallergens in Saudi Arabia
A. A. Shokeir et al. ............................................................. 2535

Treatment of Alveolar Echinococcosis with Albendazole (20 Cases)
A. Gerard et al. ............................................................... 2538

Evaluation of Antitoxoplasmic Activity of Drugs in vitro and in vivo
A. Terragna et al. ............................................................. 2540
Antimalarial Activity of Fucidic Acid in vitro
F. T. Black et al. .................................................. 2542
A New Antimycobacterial Antibiotic, Dihydromycoplanecin A: I. In vitro Activities
and Pharmacokinetics in Mice and Dogs
T. Haneishi et al. .................................................. 2544
A New Antimycobacterial Antibiotic, Dihydromycoplanecin A: II. In vivo Activities
of Dihydromycoplanecin A in Combination with Isoniazid on the Experimental
Mycobacterioses in Mice
H. Takahashi et al. .................................................. 2546
Rapid Culture of Mycobacteria Using Bactec: The Inhibitory Effect of PACT
P. Wilson et al. .................................................. 2548
Major Antibiotic Susceptibility of the Clinically Isolated Atypical Mycobacterium Strains
T. Arai et al. .................................................. 2550
Assessment of Therapeutic Efficacy of Antifungal Agents in the Animal Model
of Dermatophytosis Based on the Quantity of Chitin in the Infected
Dermal Tissues
K. Uchida and H. Yamaguchi ........................................ 2552
Effect of pH on in vitro Antifungal Drug Sensitivity Testing
D. Ellis et al. .................................................. 2554
Candida-induced Prostatic Infections: Clinical Experience with Ketoconazole
W. Bischoff .................................................. 2556
Mechanism of the Fungicidal Action of SF 86-327, a New Allylamine
Antimycotic Agent
N. S. Ryder et al. .................................................. 2558
Comparison of in vitro Activity of Five Antifungal Compounds against Clinical
Isolates of Candida albicans in Riyadh, Saudi Arabia
A. H. Ishag et al. .................................................. 2560
Effects of OK-432 on Antibody Forming Cells against Trinitrophenylated
Sheep Red Blood Cells
Y. Mizoguchi et al. .................................................. 2563
Gastroenteritis in Children in Saudi Arabia with Special Reference to Rotavirus
Infection: One-year Study
A. A. Shokeir et al. .................................................. 2565
Cytomegalovirus Infection in Renal Transplant Recipients
K. Shindo et al. .................................................. 2568
Safety and Immunogenicity of a Booster Dose of Acellular Pertussis Component
DTP Vaccine
M. Deitch et al. .................................................. 2570
The Value of Administering a Polyvalent Bacterial Vaccine in the Prevention
of Pneumonia
K. Suzuki et al. .................................................. 2572
Hypersensitivity Reactions against Antimicrobial Chemotherapeutics in Japan
H. Okubo et al. .................................................. 2574
Effect of Antibiotics on Immediate Hypersensitivity Reactions in vitro: Suppression
of IgE-mediated Histamine Release from Human Peripheral Basophils
by Fosfomycin
S. Ida et al. .................................................. 2576
An Early Cellular Effect of Cyclosporin A Is Membrane Potential Change
in Human and Mouse Lymphocytes
A. Aszalos et al. .................................................. 2578
Infection with an Acyclovir-resistant Virulent Mutant of Herpes Simplex Virus
J. W. M. van der Meer et al. .......................................................... 2580
Synergistic Inhibitory Effect of Acyclovir and Human Interferon on the Growth
of Herpes Simplex Virus in vitro
H. Kawaguchi et al. ............................................................... 2582
Effect of Antiviral Agents on the Uptake of \(^{131}\)I-Labeled
(E)-5-(2-Iodovinyl)-2'-deoxyuridine in Herpes Infected Cells
M. J. Gill et al. ............................................................... 2584
Pharmacokinetics and Metabolism of \([^{131}\]I\)-(E)-5-(2-Iodovinyl)-2'-deoxyuridine
in Dogs
J. Samuel et al. ............................................................... 2586
Trial of Inactivated Japanese Encephalitis Vaccine in High-risk Children
A. Yamada et al. ............................................................... 2588
Pharmacokinetics of FIAU in Rats and Monkeys
R. H. Barbhaiya and K. A. Pittman ............................................................... 2590
Human Cytomegalovirus Induced Host Cell Membrane Permeability
to Hygromycin B
M. P. Landini et al. ............................................................... 2592
Monoclonal Antibodies Reacting with Nuclear, Cytoplasmic and Membrane
Antigens of Human Cytomegalovirus Infected Cells
M. La Placa et al. ............................................................... 2594
Alpha-interferon Treatment in Chronic and in Acute Fulminant H.B.V. Hepatitis
P. Consoli et al. ............................................................... 2596

§16. Adverse Side Effects
Adverse Reactions in Treatment with Aminopenicillins: Data and Some
Methodological Aspects from Large International Clinical Research Programs
M. Blomqvist et al. ............................................................... 2601
The Influence of New Cephems on the Intestinal Flora
S. Iwata et al. ............................................................... 2603
Effect of Three New β-Lactams (Amoxicillin + Clavulanic Acid, Aztreonam,
Imipenem) on Aerobic Fecal Flora in Infants and Children
J. C. Borderon et al. ............................................................... 2605
Influence of Cephalosporins III Generation with Varying Biliary Elimination
on Fecal Flora and Emergence of Resistant Bacteria during Therapy
J. P. Guggenbichler et al. ............................................................... 2607
Influence of Ten Oral Antimicrobial Drugs upon Eight Biochemical
Microflora-associated Characteristics in Healthy Subjects
T. Midtvedt et al. ............................................................... 2609
β-Lactam Antibiotics Inhibit Fibrinogen Binding to Human Platelets in vitro:
A Model for Platelet Alteration in vivo
D. Heinrich et al. ............................................................... 2611
Hemostasis under Treatment with 3rd-generation Cephalosporins
K. Andrassy ............................................................... 2613
Bleeding Abnormalities in Patients Treated with Ticarcillin, Mezlocillin
or Piperacillin Plus Tobramycin in a Double-blind Randomized Clinical Study
P. Somani et al. ............................................................... 2616
Kinetics of a Methyltetrazolythiomethyl Group and Bleeding Tendencies in Animals
Y. Sato et al. ............................................................... 2619
A Study on Cephalosporin and Related Antibiotic-induced Convulsions  
S. Hori et al. ................................................................. 2621
Reduction of Dibekacin-induced Nephrotoxicity in Combination with Fosfomycin or Glucaron Sodium  
I. Nakayama et al. ........................................................ 2623
Protective Effects of Fosfomycin on Cisplatin-induced Renal Toxicity in the Mouse  
K. Tanaka et al. .............................................................. 2626
The Importance of Na Loading on Amphotericin B Nephrotoxicity Considering the Combination with 5 Flucytosine and Ticarcillin  
H. Heidemann et al. ...................................................... 2628
Acute Renal Failure Produced by Combining Cyclosporine and Brief Ischemia: Urine Sodium Effects  
D. J. McGraw et al. ............................................................ 2630
Mitochondrial Function in Experimental Gentamicin Nephrotoxicity  
W. M. Bennett et al. ....................................................... 2632
In vitro Model and Semi-empirical Conformational Analysis to Study and Compare the Intrinsic Nephrotoxicity of Aminoglycoside Antibiotics  
P. M. Tulkens et al. ....................................................... 2634
Reduced Nephrotoxicity of Gentamicin in Uremic Rats Using a Combination with Fosfomycin  
G. Sterner et al. ............................................................. 2636
Analyses of Inductive and Nephrotoxic Potential of Antibiotics: Aminoglycosides and Cephalosporins  
G. Heinert and W. Mondorf ............................................. 2638
Comparative Evaluation of the Nephrotoxicity and Effects on Prothrombin Synthesis of Cefotetan and Gentamicin  
B. Trollfors et al. ........................................................... 2641
Lesser Nephrotoxicity with Cefotaxime Compared to a Cephalosporin and Aminoglycoside Antibiotic Combination  
P. Jacobs ................................................................. 2643
Animal Study on the Nephrotoxic Potential of Gentamicin-Ceftazidime Combination Treatment at Low Doses  
M. B. Carlier et al. .......................................................... 2645
Biochemical Study on Nephrotoxicity of Gentamicin in Rats  
M. Nakazono et al. .......................................................... 2647
Nephrotoxicity of Antibiotics in Unilateral Renal Dysfunction  
S. Okada et al. .............................................................. 2649
Urinary N-Acetyl-β-glucosaminidase Activity in Patients Receiving Aminoglycoside Therapy  
K. Fujita et al. .............................................................. 2651
Prospective, Comparative, Randomized Clinical Study of Aminoglycosides Given Once a Day versus Three Times a Day in Severe Infections  
L. Nordström et al. ........................................................ 2653
Evaluation of the Nephrotoxic Potential and Pharmacokinetics of Ofloxacin under Multiple Dose Conditions  
M. Verho et al. .............................................................. 2655
Studies on the Developmental Mechanism of Hemorrhagic Tendency  
K. Sunakawa et al. ........................................................ 2657
Clinical Study of the Cause and Treatment of Plasmatic Coagulation Disorders Associated with Cephalosporins
C. D. Schwigon and D. Barckow .................................................. 2659
Influence of Antibiotics on Hemostatic Mechanism
Y. Iida et al. .................................................................................. 2661
Effect of Latamoxef, Ceftriaxone and Cefotaxime on Blood Coagulation in Patients with Intraabdominal Surgery
W. Graninger et al. ....................................................................... 2663
Effect of Indomethacin and Diclofenac on the Renal Handling and Nephrotoxicity of Gentamicin in Rabbits
B. Fantin et al. ............................................................................... 2665
Effects of Cefotaxime on the Fecal Flora in Children
N. Lambert-Zechovsky et al. .......................................................... 2667
Microbiological Implications of the Use of Cefoxitin Suppositories
L. J. Dunn et al. ............................................................................. 2669
The Effects of Oral Antimicrobial Agents upon Tryptic Activity in Feces
K. E. Norin and T. Midtvedt ............................................................ 2671
Mechanism of Mitochondrial Damage of the Surviving Hair Cells in Guinea Pigs Treated with Aminoglycoside
M. Akiyoshi et al. ............................................................................ 2673
In vitro and in vivo Studies of Ureidopenicillins: Immunogenicity and Cross-reactivity
A. Foca et al. .................................................................................. 2675
The Contracting Mechanism of Gentamicin on the Isolated Tracheal Muscle of the Guinea Pig
S. Yamada ..................................................................................... 2677
Effect of Hydroxylation of the 2', 6'-Diaminohexose Moiety on the Intrarenal Accumulation of Aminoglycoside Antibiotics: Comparison between Kanamycin B, Tobramycin, Dibekacin, and Gentamicin
L. Giurgea-Marion and P. M. Tulkens .......................................... 2679

§17. Antibiotic Policy

The Impact of Control on the Utilization of Cephalosporins in Surgical Prophylaxis in a Teaching Hospital
M. Y. Ma and J. P. Rho ................................................................. 2683
Therapeutic Substitution of Cephalosporins, an Effective Cost Containment Measure in a Community-based Teaching Hospital
T. Madhavan et al. ................................................................. 2685
Inappropriate Use of a Third-generation Cephalosporin in a Community Hospital: Effect on Cost and Prescribing Patterns of Physicians
T. Madhavan et al. ................................................................. 2687
Is Acyclovir Prophylaxis in Bone Marrow Transplantation Cost Effective?
L. G. F. Sinnige et al. ................................................................. 2689
The Effect of Introducing Cost Information on the Antibiotics Expenditure in Hospitalized Patients
E. Rubinstein et al. ................................................................. 2691
Role of the Clinical Microbiology Laboratory in Antibiotic Cost Containment: A Community Hospital Experience with Prior in vitro Evaluation and Reporting Systems
T. Madhavan et al. ................................................................. 2693
Knowledge-based Antibiotic Therapy Selection Counselling System: Anticipator  
M. Kimura et al. ........................................ 2695
Post-marketing Surveillance of Cefmetazole: Results of Five-year Survey in Japan  
Cefmetazole PMS Review Committee ........................................ 2697
Computer-evaluated Control of Infection in Internal and Surgical Care Units  
G. Scherbel et al. ........................................ 2699

Workshop Summaries

Antibacterial Concentration-response Relationships in vitro, in Animals and in Patients  
H. C. Neu ........................................ 2703
Antibiotic Suppositories  
R. Fujii and G. H. McCracken ........................................ 2709
Methicillin-resistant Staphylococcus aureus  
K. Shimada ........................................ 2716
Ciprofloxacin: Antimicrobial Activity, Pharmacokinetics and Clinical Evaluation  
G. K. Daikos and K. Mashimo ........................................ 2720
A New Quinolone Compound (Pefloxacin): Antimicrobial and Clinical Activity  
T. Nishino ........................................ 2725
Host Defense and Antibiotics  
P. G. Quie ........................................ 2728
Ofloxacin: A New Quinolone Antibacterial Agent  
S. Mitsuhashi and G. K. Daikos ........................................ 2730
A Practical Evaluation of a Significant Advance in Antibiotic Therapy  
J. S. Remington ........................................ 2735
Macrolides: A Review and the Outlook for Future Developments  
J. P. Butzler and H. Kobayashi ........................................ 2738
A Review of New Oral Cephem  
K. Shimada and R. C. Moellering, Jr ........................................ 2740
Clinical Advances in Antiviral Therapy  
P. S. Lietman ........................................ 2747
Interferon Alpha-2: Pre-clinical and Clinical Evaluations in Viral Diseases  
D. A. J. Tyrrell ........................................ 2749
Combination Therapy with Immunoglobulin and Antibiotics against Severe Infections  
R. Fujii ........................................ 2751
The Clinical Significance of Indirect Pathogenicity and the Role of \[\beta\]-Lactamase  
S. Mitsuhashi ........................................ 2753
\[\beta\]-Lactamase Blocking Agents  
Y. Ueda et al. ........................................ 2756
Penicillinase-producing Neisseria gonorrhoeae  
P. Piot ........................................ 2762
Recent Advances in Cephalosporins in the Control of Opportunistic Pathogens  
K. Ishibiki and L. O. Gentry ........................................ 2764
Monobactams: A New Approach to Antimicrobial Therapy  
H. C. Neu and Y. Ueda ........................................ 2768
Treatment of Bacteroides Infections  
S. M. Finegold and K. Ueno ........................................ 2773
Serum Bactericidal Assay: Technical Aspects and Clinical Correlations
   J. Klastersky and H. Standiford ........................................ 2775
Mixed Surgical Infections
   S. L. Gorbach ............................................................... 2776
Progress in the Treatment and Prevention of Polymicrobial Infections
   H. Kobayashi et al. ......................................................... 2778
Economics of Ceftriaxone Use
   L. Eron ................................................................. 2782
Teicoplanin: A New Clinical Candidate for Treatment of Severe
   Gram-positive Infections
   G. Gialdroni-Grassi et al. .................................................. 2785
Role of Infection in Perinatal Morbidity ................................ 2790

Indexes

Author Index ........................................................................ 2793
Subject Index ........................................................................ 2829
Disease/Pathogen Index ..................................................... 2834
Compound Index ............................................................... 2838
Abbreviations of Antimicrobial Agents Recommended by
   the Japanese Society of Chemotherapy ............................... 2843

Contents of Antimicrobial Section  1

Special Lecture ................................................................. 1
Symposia ............................................................................. 11
§ 1. New Antimicrobial Agents, Microbiology and Biochemistry 235
§ 2. Diagnostics and Susceptibility ......................................... 431
§ 3. Pharmacokinetics ......................................................... 623
§ 4. Experimental Infection ................................................... 747
§ 5. Immunology ................................................................. 789

Contents of Antimicrobial Section  2

§ 6. Cepham Antibiotics ....................................................... 875
§ 7. Penem and Penam Antibiotics .......................................... 1187
§ 8. Monobactams ................................................................ 1329
§ 9. Macrolide Antibiotics .................................................... 1403
§10. Quinolone Antibacterials ............................................... 1513